Home/Pipeline/Undisclosed MS Program

Undisclosed MS Program

Multiple Sclerosis

Pre-clinicalActive

Key Facts

Indication

Multiple Sclerosis

Phase

Pre-clinical

Status

Active

Company

Astoria Biologica

About Astoria Biologica

Astoria Biologica is a private, preclinical-stage biotech focused on autoimmune and inflammatory diseases, particularly Multiple Sclerosis. The company employs a biologics and antibody-based therapeutic approach to develop novel treatments. As a young, venture-backed firm, it is in the early stages of research and development, positioning itself in a high-need, high-value therapeutic market. Its success will hinge on advancing its pipeline into clinical trials and securing strategic partnerships or further funding.

View full company profile

Therapeutic Areas

Autoimmune Diseases Inflammatory Diseases Multiple Sclerosis

Other Multiple Sclerosis Drugs

Drug	Company	Phase	Status
Mimotopes-003	Mimotopes	Preclinical	Active
SPU-16	Silo Pharma	Preclinical	Research
Electroceutical® Therapy	Endonovo Therapeutics	Research	Active
IMX39	Imunexus Therapeutics	Preclinical	Active
BTK allosteric inhibitor	Acellera	Pre-clinical	Early Hit
CLS12311	Cellerys	Phase 2	Active
Interferon-beta variants	Heligenics	Pre-clinical	Active
G-NK cells	Indapta Therapeutics	Phase 1	Active
MS Biomarker Research	Rune Labs	Research	Active
AVT001	Avotres	Phase 2b	Active
PV-3212	Provid Pharma	Pre-clinical	Active
Evobrutinib	EMD Serono	Phase 3	Active